Web2 dagen geleden · “We must now wait for the results of ongoing phase III trials, such as SAPPHIRE with sitravatinib plus nivolumab, Pragmatica-Lung with ramucirumab plus pembrolizumab, and LEAP-008 with pembrolizumab plus lenvatinib, to establish whether we can expand second-line treatment options for our patients.” Abstract discussed: Web1 jan. 2024 · In the treatment of metastatic lung cancer, individual treatments have been applied to the discovery of driver mutations in recent years. Epidermal growth factor ... et …
Overall Treatment Strategy for Patients With Metastatic NSCLC …
Web13 apr. 2024 · This is an open-label, single-intervention, multicenter clinical trial in patients with non-small cell lung cancer with asymptomatic or mildly symptomatic brain metastases after failure of EGFR TKI treatment. The objective of this study is as follows. Primary objective : intracranial objective response rate (iORR) with RECIST 1.1 Web29 mei 2024 · Activation of the hepatocyte growth factor (HGF)–MET pathway can lead to gefitinib resistance in EGFR-mutant non-small-cell lung cancer (NSCLC) by activating … childhood lead poisoning advisory committee
Cancers Free Full-Text Efficacy and Safety of Epidermal Growth ...
WebIn patients with non–small-cell lung cancer that initially responds to gefitinib or erlotinib, an acquired resistance to EGFR inhibitors, resulting in treatment failure, is associated with … Web25 aug. 2024 · We present a 52-year-old male patient with metastatic non-small-cell lung cancer (NSCLC). The patient was found to have L858R mutation in exon 21 of the … Web16 jul. 2024 · The researchers think that the study drugs, amivantamab and lazertinib, may be an effective treatment for people who have metastatic NSCLC with an EGFR mutation. Both drugs work to target cancer cells with an EGFR mutation, and this targeting action could stop or slow the growth of cancer cells. got spinoff release date